Example: Heart Attack

Clinical Trials Sponsored by Threshold Pharmaceuticals

Total 33 results

NCT03098160

Unknown status

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Conditions: Pancreatic Cancer; Melanoma; Squamous Cell Carcinoma of the Head and Neck; Prostate Cancer
NCT02454842

Terminated

Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC

Conditions: Non-small Cell Lung Cancer; NSCLC; Non-squamous NSCLC
NCT02449681

Terminated

Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS

Conditions: Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin
NCT02093962

Terminated

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

Conditions: Non-small Cell Lung Cancer
NCT02047500

Terminated

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

Conditions: Pancreatic Cancer
NCT02020226

Unknown status

A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors

Conditions: Solid Tumors
NCT01864538

Terminated

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

Conditions: Metastatic Melanoma
NCT01746979

Completed

Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

Conditions: Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
NCT01522872

Unknown status

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Conditions: Multiple Myeloma
NCT01440088

Completed

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Conditions: Soft Tissue Sarcoma
NCT01381822

Unknown status

Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors

Conditions: Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Pancreatic Neuroendocrine Tumors
NCT01149915

Completed

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Conditions: Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Chronic Myelogenous Leukemia; High-risk Myelodysplastic Syndrome; Chronic Lymphocytic Leukemia; Advanced Myelofibrosis
NCT01144455

Completed

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

Conditions: Pancreatic Adenocarcinoma
NCT00743379

Completed

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

Conditions: Non-Small Cell Lung Cancer; Prostate Cancer; Pancreatic Cancer
NCT00742963

Completed

Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma

Conditions: Soft Tissue Sarcoma
NCT00495144

Completed

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors

Conditions: Tumors; Hypoxia
NCT00435578

Terminated

Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma

Conditions: Carcinoma, Small Cell Lung
NCT00435448

Terminated

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

Conditions: Benign Prostatic Hyperplasia; Enlarged Prostate
NCT00237536

Terminated

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

Conditions: Benign Prostatic Hyperplasia
NCT00102752

Completed

Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer

Conditions: Neoplasms; Pancreatic Neoplasms
NCT00099294

Completed

Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer

Conditions: Pancreatic Cancer
NCT00096707

Completed

Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors

Conditions: Lung Cancer; Breast Cancer; Pancreatic Cancer; Head and Neck Cancer; Gastric Cancer
NCT02712567

No longer available

SARC021C: A Continuation Study of TH-CR-406/SARC021

Conditions: Soft Tissue Sarcoma
NCT02433639

Completed

Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer

Conditions: Biliary Tract Cancer
NCT02255110

Terminated

A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Conditions: Soft Tissue Sarcoma